C-reactive Protein Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global C-reactive Protein Testing Market was valued at approximately USD 3.2 billion in 2023 and is projected to reach around USD 4.4 billion by 2032, reflecting a CAGR of 3.9% from 2024-2032. This growth is driven by the rising prevalence of chronic disorders and an increasing demand for CRP testing, crucial for diagnosing and managing these conditions. Chronic ailments like rheumatoid arthritis, cardiovascular diseases, and diabetes require consistent monitoring and management, facilitated by CRP testing. The uptick in these chronic conditions has intensified the reliance on CRP tests for early detection and ongoing management. The World Health Organization (WHO) reported in 2023 that chronic diseases accounted for 71% of global deaths, highlighting the urgent need for effective diagnostic and monitoring tools. Consequently, this surge in chronic diseases is propelling the global demand for CRP testing.

The overall C-reactive protein testing industry is classified based on the detection range, product, assay type, application, and region.

Segmented by product, the C-reactive protein testing market includes instruments, kits, and reagents. In 2023, the kits and reagents segment led the market, generating revenues of USD 2 billion. Kits and reagents are versatile and compatible with various instruments and platforms. This adaptability caters to diverse CRP assays, including enzyme-linked immunosorbent assay, immunoturbidimetric assay, and chemiluminescence immunoassay, enhancing their appeal across multiple clinical environments. Many CRP testing kits prioritize user-friendliness and rapid results. Such features are vital in clinical settings where timely decisions are paramount, making these kits more appealing than intricate, time-consuming methods.

Assay types in the C-reactive protein testing market include chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and others. The immunoturbidimetric assay segment is projected to lead the market with anticipated revenues of USD 1.6 billion during the forecast period. Immunoturbidimetric assays stand out for their affordability, especially compared to pricier options like CLIA and ELISA. This cost advantage appeals to a broad spectrum of healthcare providers, notably smaller clinics and budget-constrained laboratories. These assays are celebrated for their swift processing and efficiency.

In 2023, North America accounted for USD 1.2 billion in the C-reactive protein testing market and is poised for significant growth in the coming years. The region grapples with a high prevalence of chronic diseases, notably cardiovascular ailments and diabetes. This uptick drives the demand for CRP testing, as monitoring CRP levels is common for assessing inflammation in these conditions. North America's advanced healthcare infrastructure and broad access to diagnostic technologies further fuel the CRP testing market. The region's embrace of innovative diagnostic tools and a proactive stance on early disease detection amplify CRP test usage.

Product Code: 10749

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic disorders such as inflammatory diseases
  - 3.2.1.2 Surge in demand for CRP testing for diagnosis and management of chronic diseases
  - 3.2.1.3 Advances in technology
  - 3.2.1.4 Growing demand for direct-to-home testing services
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of standardization
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Reimbursement scenario
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Kits and reagents

Chapter 6 Market Estimates and Forecast, By Assay Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemiluminescence immunoassay (CLIA)
6.3 Enzyme-linked immunosorbent assay (ELISA)
6.4 Immunoturbidimetric assay
6.5 Other assay types

Chapter 7 Market Estimates and Forecast, By Detection Range, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 High-sensitivity CRP (hs-CRP)
7.3 Standard CRP

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Cardiovascular diseases
8.3 Infectious diseases
8.4 Chronic inflammatory diseases
8.5 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic laboratories
9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

11.1 Abbott
11.2 Agilent technologies
11.3 Aidian
11.4 Boditech Med, Inc.
11.5 Creative diagnostics
11.6 CTK Biotech
11.7 Danaher
11.8 DxGen Corp
11.9 F. Hoffmann-La Roche Ltd.
11.10 Getein Biotech, Inc.
11.11 Goldsite diagnostics
11.12 HORIBA, Ltd
11.13 Laboratory Corporation of American Holding
11.14 LumiraDX
11.15 Merck KGaA
11.16 Optibio co., Ltd
11.17 Randox Laboratories Ltd.
11.18 Siemens Healthineers AG